[1]
|
FDA, “PAT—A Framework for Innovative Pharmaceu- tical Manufacturing and Quality Assurance,” 2004.
http://fda.gov/cder
|
[2]
|
E. W. Ciurczak and J. K. Drennen, “Practical Spectros- copy Series: Pharmaceutical d Medical Applications of Near-Infrared Spectroscopy,” Marcel Dekker, New York, 2002.
|
[3]
|
W. Plugge and C. Van der Vlies, “The Use of Near In- frared Spectroscopy in the Quality Control Laboratory of the Pharmaceutical Industry,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 10, No. 10-12, 1992, pp. 797-803. doi:10.1016/0731-7085(91)80083-L
|
[4]
|
C. I. Gerh¨ausser and K. A. Kovar, “Strategies for Constructing Near-Infrared Spectral Libraries for the Identification of Drug Substances,” Applied Spectroscopy, Vol. 51, No. 10, 1997, pp. 1504-1510.
doi:10.1366/0003702971939000
|
[5]
|
M. J. Vredenbregt, P. W. J. Caspers, R. Hoogerbrugge and D. M. Barends, “Choice and Validation of a Near Infrared Spectroscopic Application for the Identity Control of Starting Materials.: Practical Experience with the EU Draft Note for Guidance on the Use of Near Infrared Spectroscopy by the Pharmaceutical Industry and the Data to be Forwarded in Part II of the Dossier for a Marketing Authorization,” European Journal of Pharmaceutics and Biopharmaceutics, Vol. 56, No. 3, 2003, pp. 489-499. doi:10.1016/S093
|
[6]
|
S. S. Sekulic, H. W. Ward and P. K. Aldridge, “On-Line Monitoring of Powder Blend Homogeneity by Near-In- frared Spectroscopy,” Analytical Chemistry, Vol. 68, No. 3, 1996, pp. 509-513. doi:10.1021/ac950964m
|
[7]
|
P. Merckle and K.-A. Kovar, “Assay of Effervescent Tablets by Near-Infrared Spectroscopy in Transmittance and Reflectance Mode: Acetylsalicylic Acid in Mono and Combination Formulations,” Journal of Pharmaceutical and Biomedical Analysis, Vol. 17, No. 3, 1998, pp. 365- 374. doi:10.1016/S0731-7085(97)00194-5
|
[8]
|
R. P. Cogdill, C. A. Anderson and J. K. Drennen, Phar- maceutical Technology, 2004, pp. 29-34.
|
[9]
|
J. Sun, Journal of Chemometrics, Vol. 11, 1997, pp. 525-532.
|
[10]
|
R. J. Barnes, M. S. Dhanoa and S. J. Lister, “Standard Normal Variate Transformation and De-trending of Near- Infrared Diffuse Reflectance Spectra,” Applied Spectros- copy, Vol. 43, No. 5, 1989, pp. 772-777.
doi:10.1366/0003702894202201
|
[11]
|
T. Fearn, NIR News, Vol. 10, 1999, pp. 10-11.
|
[12]
|
ICH Q2B, International Conference on Harmonisation, Validation of Analytical Procedures, Methodology, 2002.
|
[13]
|
FDA, “Guidance for Industry: Validation of Analytical Procedures,” Food and Drug Administration, Rockville, 1997.
|
[14]
|
International Conference on Harmonisation Topic Q2B, “Validation of Analytical Methods: Methodology,” The Third International Conference on Harmonization of Technical Requirements for Registration of Pharmaceu- ticals for Human Use (ICH) Yokohama-Japan.
|
[15]
|
Y. V. Heyden, A. Nijhuis, J. Smeyers-Verbeke and B. G. M. Vandeginste D. L., Journal of Pharmaceutical and Biomedical Analysis, 2001, p. 24723.
|
[16]
|
A. Eustaquio, P. Graham, R. D. Jee, A. C. Moffat and A. D. Trafford, “Quantification of Paracetamol in Intact Tablets Using Near-Infrared Transmittance Spectros- copy,” Analyst, Vol. 123, No. 11, 1998, pp. 2303-2306.
doi:10.1039/a804528c
|
[17]
|
R. Ragonese, M. Mulholland and J. Kalman, “Full and Fractionated Experimental Designs for Robustness Test- ing in the High-Performance Liquid Chromatographic Analysis of Codeine Phosphate, Pseudoephedrine Hy- drochloride and Chlorpheniramine Maleate in a Pharma- ceutical Preparation,” Journal of Chromatography A, Vol. 870, No. 1-2, 2000, p. 45.
doi:10.1016/S0021-9673(99)00972-3
|
[18]
|
G. A. Lewis, D. Mathieu and R. Phan-Tan-Luu, “Phar- maceutical Experimental Design,” Marcel Dekker, New York, 1999.
|